Permira appoints Mubasher Sheikh as new Head of Healthcare

Posted on: 22 February 2012

Permira today announces the appointment of Mubasher Sheikh as Head of its Healthcare team. Mubasher brings over 15 years of healthcare experience, both in medical practice and as a management consultant.#

 

Prior to joining Permira, Mubasher  spent 11 years at McKinsey & Co, including six as Partner, playing multiple roles including Head of the Global Pharmaceutical R&D Practice and McKinsey’s European Healthcare Private Equity and Principal Investing industry. He originally qualified as a doctor from the University of London and worked as a transplant physician and lecturer at teaching hospitals in London and Cambridge.

 

As a former Partner at McKinsey, Mubasher managed a client portfolio ranging from start-ups to top tier pharmaceutical companies, including over half of the world’s leading pharmaceutical, biotech and medical devices companies. He has undertaken over 80 projects over the last ten years and advised boards on strategy and improvement issues with a particular emphasis on improving growth, M&A and technology.

 

Mubasher replaces Sally Flanagan who has decided to step down from a full time role but remains with Permira on a part-time basis to work on selected investment opportunities.

 

Commenting on the appointment, Kurt Björklund, Co-Managing Partner of Permira, said: “We are delighted to welcome Mubasher to the Permira team. He brings a deep industry knowledge and network which will be invaluable to the firm as we continue to strengthen our presence in the healthcare sector. We look forward to working with him on finding attractive investment opportunities for our funds.” 

 

“We would also like to thank Sally for her contribution in setting up and developing our Global Healthcare team since 2008. Thanks to her efforts we have a strong team in place today and are well positioned to capture future opportunities in the sector.”

 

Mubasher Sheikh added: “It is a very exciting time to be joining Permira. Societal changes, economic pressures and risk management issues create many opportunities for long-term investment in the pharmaceuticals, med-tech and healthcare services sub-sectors. I look forward to working with the team on finding quality growing assets for the funds to invest in.”

Readers Comments